Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?

Basit Öğe Kaydı
dc.authoridKose, Fatih/0000-0002-0156-5973
dc.authoridBesen, Ayberk/0000-0002-7862-0192
dc.authoridSumbul, Ahmet Taner/0000-0002-5573-906X
dc.authoridsezer, ahmet/0000-0002-6445-1439
dc.authoridOzyilkan, Ozgur/0000-0001-8825-4918
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorDisel, Umut
dc.contributor.authorSezgin, Nurzen
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKose, Fatih
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorSumbul, Zehra
dc.date.accessioned2024-09-18T19:54:22Z
dc.date.available2024-09-18T19:54:22Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there is no established single marker that can be used as a predictive marker in bevacizumab therapy. Material/Methods: We enrolled 24 patients with the diagnosis of metastatic colorectal cancer in our study. During the study, 2 blood samples were drawn from patients before the first cycle and after the sixth cycle of bevacizumab therapy. Serum levels of VEGF, ANG II, and NO were recorded. Results: While the change across VEGF levels was found to be a statistically significant decreasing trend (p=0.009), this decrease was not found to be correlated with treatment response and hypertension development. Additionally, no statistically significant difference was found in terms of NO and ANG II levels. Conclusions: This study showed a significant decrease in serum VEGF, but failed to show a significant change in NO and ANG II levels during bevacizumab treatment. Although no significant correlation was found between the presence of hypertension and markers, most patients (83%) had an increase in their blood pressure. Our results suggest that dynamic monitoring of NO and ANG II, along with VEGF, may not be useful as predictive markers for bevacizumab treatment in colorectal cancer.en_US
dc.description.sponsorshipTurkish Medical Oncology Societyen_US
dc.description.sponsorshipThis study was performed with a grant from the Turkish Medical Oncology Societyen_US
dc.identifier.endpage433en_US
dc.identifier.issn1643-3750
dc.identifier.pmid24632679en_US
dc.identifier.scopus2-s2.0-84897904203en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage428en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7689
dc.identifier.volume20en_US
dc.identifier.wosWOS:000332857500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInt Scientific Information, Incen_US
dc.relation.ispartofMedical Science Monitoren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAngiotensin II - diagnostic useen_US
dc.subjectColorectal Neoplasmsen_US
dc.subjectBevacizumaben_US
dc.subjectNitric Oxide - diagnostic useen_US
dc.subjectVascular Endothelial Growth Factorsen_US
dc.titleCan serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
7689.pdf
Boyut:
500.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu